FDA Inspection
Bristol-Myers Squibb CompanyBristol-Myers Squibb Company – FDA Inspection, Sep 6, 2024
Record Details
This FDA Inspection record concerns Bristol-Myers Squibb Company, with an inspection on September 6, 2024, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · b8ae4944-d185-4142-8468-e00f31678546
Inspection Facts
No Action Indicated (NAI)
No objectionable conditions or practices were found during the inspection.
- Inspection number
- 1247735
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
Other FDA inspections of Bristol-Myers Squibb Company
16| Date | Classification | Office | Project area |
|---|---|---|---|
| June 23, 2026 | Not classified | New Jersey District Office | |
| July 18, 2025 | Not classified | New Jersey District Office | |
| December 6, 2024 | VAI | New Jersey District Office | Postmarketing Surveillance and Epidemiology: Human Drugs |
| January 31, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| June 16, 2023 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
Other documents for Bristol-Myers Squibb Company
- FDA Inspection 1327472 - 2026-06-23
- FDA Inspection 1275526 - 2025-07-18
- FDA Inspection 1236864 - 2024-12-06
- FDA Inspection 1228973 - 2024-01-31
- FDA Inspection 1208871 - 2023-06-16
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.